Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

Vandana Singh

Thu, May 13, 2021, 6:52 AM1 min read

Celyad Oncology SA (NASDAQ: CYAD) has announced initial clinical data from the Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in patients with relapsed or refractory multiple myeloma.
The data will be presented at the upcoming European Hematology Association (EHA) Virtual Congress 2021.
No severe/life-threatening treatment-related adverse events nor evidence of Graft-versus-Host disease were reported from the completed first dose-level (DL1) cohort of the trial.
Initial results at a low dose of 30x106 cells per infusion showed preliminary signs of clinical activity, including a confirmed partial response.
CYAD-211 is an investigational, non-gene edited allogeneic CAR T candidate engineered to co-express a single hairpin RNA (shRNA) and a BCMA-targeting chimeric antigen receptor.
Price Action: CYAD shares are trading 21.9% higher at $6.47 during the premarket session on the last check Thursday.

See more from Benzinga

Jeff Bezos' Most Prized Possession Breaks Historical Auction Records At Almost $53 Million
Jeff Bezos amassed his wealth through Amazon stocks and owns hundreds of millions of dollars worth of real estate, but one of his most valuable possessions may surprise you: art. Among his collection is the renowned piece "Hurting the Word Radio #2 (1964)" by Ed Ruscha, purchased by Bezos for almost $53 million. This artwork, a prime example of Ruscha’s text-based paintings, stands as a signature piece in Bezos’ collection. As concerns over stock market volatility persist, the world’s wealthiest
Benzinga
Warren Buffett's Latest $2.6 Billion Buy Brings His Total Investment in This Stock to More Than $77 Billion in Under 6 Years
The Oracle of Omaha has purchased shares of his favorite stock for 23 consecutive quarters.
Motley Fool
McDonald’s Will Offer a $5 Meal Deal to Lure Customers Back Into Stores
(Bloomberg) -- McDonald’s Corp. is looking to launch a $5 meal deal in the US that the burger chain is betting can lure penny-pinching consumers back in.Most Read from BloombergElon Musk Pledges to Grow Supercharger Business He Just DecimatedBiden Set to Hit China EVs, Strategic Sectors With TariffsAckman Scolded Over DEI Views at Closed-Door Milken SessionJim Simons, Code Breaker Who Mastered Investing, Dies at 86Apple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TVThe deal could includ
Bloomberg
Nvidia Dethroned: This AI Chip Stock Now Rules This Elite Screen
Broadcom just ended the reign of Nvidia, usurping the top spot on this list of new buys by the best mutual funds.
Investor's Business Daily
The feds may crack down on credit-card rewards programs. Here’s what that means for your points and miles.
The Department of Transportation and the Consumer Financial Protection Bureau are exploring possible regulation of the credit-card rewards system and the frequent-flier programs linked to them, officials said at a joint hearing held by the DOT and CFPB on Thursday.
MarketWatch
Here's the Income and Net Worth You Need to Reach the Top 50% of American Households
Americans can improve their net worth through prudent budgeting and smart investments.
Motley Fool
Chip Workers Are Likely to Quit Jobs, Worsening Labor Shortage
(Bloomberg) -- At a time when the US is looking to attract more skilled workers to semiconductor manufacturing, many current employees are rethinking whether they want to stick around, according to a McKinsey & Co. report that underscores the chip industry’s labor challenges.Most Read from BloombergElon Musk Pledges to Grow Supercharger Business He Just DecimatedBiden Set to Hit China EVs, Strategic Sectors With TariffsAckman Scolded Over DEI Views at Closed-Door Milken SessionJim Simons, Code B
Bloomberg
Trump ‘offered to block electric car rollout’ as he asked oil bosses for $1bn
Donald Trump told oil industry executives he would dismantle Joe Biden’s pro-electric vehicle agenda as he asked for $1bn (£800m) to help return him to the White House, it has been claimed.
The Telegraph
Macrogenics Stock Drops 77% After Study Deaths
MacroGenics shares plunged 77.4% on Friday, erasing $773.2 million in market value, after the biotech reported late Thursday that five patients died in a study of the company’s cancer drug. MacroGenics said two of the deaths were deemed unrelated to the drug, known as vobra duo, according to researchers. “The cause and effect with regard to the drug is still being investigated,” Chief Executive Scott Koenig said of the three deaths on the company's first quarter earnings call on Thursday.
The Wall Street Journal
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor bought into one of Thursday's biggest losers and two stocks that have fallen sharply over the past year.
Motley Fool

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy

Recommended Stories

Jeff Bezos' Most Prized Possession Breaks Historical Auction Records At Almost $53 Million

Warren Buffett's Latest $2.6 Billion Buy Brings His Total Investment in This Stock to More Than $77 Billion in Under 6 Years

McDonald’s Will Offer a $5 Meal Deal to Lure Customers Back Into Stores

Nvidia Dethroned: This AI Chip Stock Now Rules This Elite Screen

The feds may crack down on credit-card rewards programs. Here’s what that means for your points and miles.

Here's the Income and Net Worth You Need to Reach the Top 50% of American Households

Chip Workers Are Likely to Quit Jobs, Worsening Labor Shortage

Trump ‘offered to block electric car rollout’ as he asked oil bosses for $1bn

Macrogenics Stock Drops 77% After Study Deaths

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought